Literature DB >> 28145025

Association between high cumulative dose of benzodiazepine in Chinese patients and risk of dementia: a preliminary retrospective case-control study.

Tsz-Tai Chan1,2, William Chun-Yin Leung1,2, Victor Li1,2, Kin-Yiu Wesley Wong1,2, Wing-Ming Chu1,2, Ka-Chun Leung1,2, Yuey-Zhun Ng1,2, Yuen-Ming Gary Kai1,2, Yat-Fung Shea1, Shek-Kwan Richard Chang2, Leung-Wing Chu3,4.   

Abstract

BACKGROUND: Evidence describing the association between high-dose benzodiazepine use and dementia has been conflicting. Most previous studies involved Caucasian populations, with only limited data on Chinese subjects. Possible differences exist between Chinese and Caucasian populations with regard to metabolism and prescription practice. This study aimed to assess the association between high-dose benzodiazepine use and dementia in a Chinese population.
METHOD: A retrospective case-control study was carried out in all public hospitals under the Hong Kong Hospital Authority Hong Kong West Cluster between 2000 and 2015. The study recruited 273 Chinese adults (91 cases, 182 controls) aged 75 and over, with at least 6 years of follow-up data. Each dementia case was matched with two controls according to sex, age group, and duration of follow-up. The number of patients with benzodiazepine ever-use and the exposure density based on the prescribed daily doses were assessed. Prescribed daily doses were categorized as either <1096 or ≥1096. Odds ratios and 95% confidence intervals were computed by multivariate analysis.
RESULTS: The difference in exposure density between the dementia and control groups was statistically significant between prescribed daily doses <1096 and ≥1096 (P = 0.02). There were two multivariate analyses models; one factored in depression (model 1), and the other (model 2) did not. Model 2 showed a statistically significant association (odds ratio = 1.71, 95% confidence intervals = 1.02-2.89, P = 0.04) between benzodiazepine exposure density and dementia.
CONCLUSION: High-dose benzodiazepine use may be associated with dementia in the Chinese population. Prospective studies are required.
© 2017 Japanese Psychogeriatric Society.

Entities:  

Keywords:  Chinese; benzodiazepine; dementia

Mesh:

Substances:

Year:  2017        PMID: 28145025     DOI: 10.1111/psyg.12239

Source DB:  PubMed          Journal:  Psychogeriatrics        ISSN: 1346-3500            Impact factor:   2.440


  6 in total

Review 1.  Drug interactions with dementia-related pathophysiological pathways worsen or prevent dementia.

Authors:  Romain Barus; Johana Béné; Julie Deguil; Sophie Gautier; Régis Bordet
Journal:  Br J Pharmacol       Date:  2019-03-31       Impact factor: 8.739

2.  A Systematic Review and Meta-Analysis of the Risk of Dementia Associated with Benzodiazepine Use, After Controlling for Protopathic Bias.

Authors:  Ross Penninkilampi; Guy D Eslick
Journal:  CNS Drugs       Date:  2018-06       Impact factor: 5.749

Review 3.  Comparing the efficacy of benzodiazepines and serotonergic anti-depressants for adults with generalized anxiety disorder: a meta-analytic review.

Authors:  Angelina F Gomez; Abigail L Barthel; Stefan G Hofmann
Journal:  Expert Opin Pharmacother       Date:  2018-05-28       Impact factor: 3.889

Review 4.  Effects of Microbiota Imbalance in Anxiety and Eating Disorders: Probiotics as Novel Therapeutic Approaches.

Authors:  Elisabet Navarro-Tapia; Laura Almeida-Toledano; Giorgia Sebastiani; Mariona Serra-Delgado; Óscar García-Algar; Vicente Andreu-Fernández
Journal:  Int J Mol Sci       Date:  2021-02-26       Impact factor: 5.923

Review 5.  Benzodiazepines and Z-Drugs: An Updated Review of Major Adverse Outcomes Reported on in Epidemiologic Research.

Authors:  Jaden Brandt; Christine Leong
Journal:  Drugs R D       Date:  2017-12

6.  Association Between Z Drugs Use and Risk of Cognitive Impairment in Middle-Aged and Older Patients With Chronic Insomnia.

Authors:  Fang Guo; Li Yi; Wei Zhang; Zhi-Jie Bian; Yong-Bo Zhang
Journal:  Front Hum Neurosci       Date:  2021-12-09       Impact factor: 3.169

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.